{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-019053","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.231899+00:00","generated_at":"2026-06-03T05:22:47.974162+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Cumberland Pharmaceuticals shareholders re-elect directors, ratify auditor at annual meeting","bullets":["Martin S. Brown, Jr. re-elected as Class II director with 96.0% of votes in favor (8,544,756 for, 352,239 withheld).","James R. Jones re-elected as Class II director with 94.5% of votes in favor (8,411,468 for, 485,527 withheld).","Ratification of Carr, Riggs & Ingram LLC as auditor for FY2024 passed with 99.9% of votes in favor (11,189,440 for, 15,502 against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-019053","json":"https://secwatch.observer/filing/0001628280-24-019053.json","markdown":"https://secwatch.observer/filing/0001628280-24-019053.md","text":"https://secwatch.observer/filing/0001628280-24-019053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024019053/0001628280-24-019053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024019053/cpix-20240429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:22:47.974162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09c219b79e806686f3c8210de96fd4bd329eb13d","claim":"CUMBERLAND PHARMACEUTICALS INC shareholders approved Election of two Class II Directors at the 2024-04-23 meeting.","evidence_excerpt":"For Against Withheld Abstentions % of Votes in Favor Martin S. Brown, Jr. 8,544,756 — 352,239 — 96.0% James R. Jones 8,411,468 — 485,527 — 94.5%","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024019053/0001628280-24-019053-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-23"}],"fact_type":"shareholder_vote"},{"claim_id":"f2fa7176030a62c45fe1311cc75c952e17984e82","claim":"CUMBERLAND PHARMACEUTICALS INC shareholders approved Ratification of appointment of Carr, Riggs & Ingram, LLC as independent registered public accounting firm for year ending December 31, 2024 at the 2024-04-23 meeting.","evidence_excerpt":"Appointment of Carr, Riggs & Ingram LLC as our independent registered public accounting firm for the year ending December 31, 2024 11,189,440 15,502 — 28,560 99.9%","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024019053/0001628280-24-019053-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-23"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}